Influx Healthtech Limited H1 FY27 Revenue Rises 27.9% to ₹85.4 Crore

Influx Healthtech Limited reported revenue from operations of ₹85.4 crore in H1 FY27, up 27.9% year-on-year, while EBITDA increased 25.1% to ₹18.3 crore and profit after tax rose 20.0% to ₹12.0 crore. The results show continued operating growth as the company spends on new manufacturing capacity.

What did Influx Healthtech report for H1 FY27?

Influx Healthtech Limited reported a 27.9% year-on-year increase in revenue from operations to ₹85.4 crore for H1 FY27. EBITDA rose 25.1% year-on-year to ₹18.3 crore, while profit after tax increased 20.0% to ₹12.0 crore, according to its investor presentation and earnings-call disclosures.

The reported EBITDA margin was 21.5%. This indicates that earnings growth broadly tracked the expansion in revenue during the half-year, although PAT growth was lower than the increase in EBITDA. The company operates across nutraceuticals, cosmetics and ayurveda, with capacity expansion and product diversification cited in earlier company disclosures as operating drivers.

Influx Healthtech shared its H1 FY27 investor presentation before its investor conference call on November 5, 2026. It subsequently made the audio recording of that call available on its website. The company has also released the conference-call transcript, which provided management commentary on growth, margins and capacity additions.

What is driving Influx Healthtech's capacity expansion?

Influx Healthtech is expanding its production infrastructure, with civil construction at its 75,000 square feet Palghar facility described as nearly complete. The company said commercial production at the facility is targeted in the coming months, making the project a central part of its planned capacity increase.

Management said during the Q2 FY27 call that the new facility was expected to become operational between December 2026 and January 2027. It indicated that the facility could contribute around 20% additional revenue in Q4 after commissioning. This is management guidance rather than reported financial performance.

Capital expenditure is already visible in the half-year cash-flow and balance-sheet disclosures. Operating cash flow stood at ₹7.2 crore in H1 FY27, while purchases of property, plant, equipment and intangible assets totalled ₹19.9 crore. Capital work in progress was ₹15.0 crore at the end of the period.

The difference between operating cash generation and capital deployment reflects the investment phase underway. The announced Palghar project, once commissioned, is intended to add manufacturing capacity rather than represent a completed contribution to H1 FY27 revenue or profit.

What guidance has management given on revenue and margins?

Influx Healthtech management has indicated a target of about 20% to 25% revenue growth in upcoming quarters, supported by commissioning of new capacity. For FY27, management had previously stated a minimum revenue-growth expectation of 25% to 30%, with the possibility of exceeding that range based on execution.

The company has set an EBITDA-margin objective of around 21%, while describing 18% to 20% as a conservative range. Management also said gross margins were around 40% to 41% and that it was working to maintain or modestly improve EBITDA margins towards 21% to 22% over the next two to three years, subject to product-mix changes.

Management has also outlined a longer-term revenue-potential objective of ₹450 crore to ₹500 crore over two-and-a-half to three years, covering FY28 to FY29. That figure is a capacity-led management target and should not be treated as a forecasted financial result.

How do the results affect investors and operations?

The H1 numbers provide investors with reported evidence of top-line and profit growth, alongside a 21.5% EBITDA margin. Revenue growth of 27.9% was ahead of the 20% to 25% quarterly growth range subsequently outlined by management, although half-year growth and future-quarter guidance are not directly comparable periods.

The key operating issue remains capacity commissioning. Investors will be watching whether the Palghar facility starts commercial production within the December 2026 to January 2027 timetable stated on the earnings call, and whether its contribution aligns with management's indication of around 20% additional Q4 revenue.

The capex programme is material relative to the ₹7.2 crore operating cash flow reported for the half-year. It demonstrates the company is directing funds towards manufacturing expansion, but it also means that progress on construction, commissioning and utilisation will be important factors in assessing returns on that spending.

No share-price movement, valuation change or market reaction was disclosed in the material provided. Therefore, the available information supports an assessment of the company's operating performance and investment plans, not a conclusion on how the stock market has priced the results.

How does H1 FY27 compare with earlier disclosed performance?

Influx Healthtech's earlier disclosure for H2 FY26, ended March 31, 2026, reported revenue of ₹80.069 crore and net profit of ₹10.5459 crore. These figures relate to a different six-month period and are not presented by the company as a year-on-year comparison with H1 FY27.

The current H1 FY27 release is more significant for its combination of reported financial growth and details of expansion spending. It links a ₹85.4 crore half-year revenue base with a ₹15.0 crore capital-work-in-progress balance and a nearly completed 75,000 square feet Palghar facility.

For the wider nutraceutical and contract-manufacturing business, capacity availability can influence the ability to serve additional customer volumes and product categories. Influx Healthtech's disclosures identify its expansion projects and margin targets, but they do not provide customer-level contracts, order-book figures or plant utilisation data.

Conclusion

Influx Healthtech delivered H1 FY27 revenue growth of 27.9% to ₹85.4 crore, with EBITDA of ₹18.3 crore and PAT of ₹12.0 crore. The results point to continued growth with EBITDA margin maintained at 21.5%, while the company simultaneously increased investment in production assets and projects under construction.

The next disclosed execution milestone is the planned commissioning of the Palghar facility between December 2026 and January 2027. Investors will watch the timing of commercial production, the facility's contribution to Q4 revenue, capex progress and whether management maintains its stated 20% to 25% near-term growth and around 21% EBITDA-margin objectives.